---
processed: 2025-12-16
themes:
  - drug-discovery
  - foundation-models
  - valuation
---

# CHai Discovery's drug discovery approach

**Created:** 12/15/2025 9:25:02
**Updated:** 12/15/2025 12:30:32
**Exported:** 12/15/2025 21:18:29
**Link:** [https://claude.ai/chat/d9c8365b-6417-4fda-9c7c-70633408dfcb](https://claude.ai/chat/d9c8365b-6417-4fda-9c7c-70633408dfcb)  

## Response:
12/15/2025, 9:26:04 AM

I'll fetch that article to learn about CHai Discovery and their approach.

````plaintext
Web Fetch: Fetched: Chai Discovery becomes newest AI unicorn, raising $130M Series B at $1.3B valuation
````

The article requires a sign-up to read the full content. Let me search for more information about CHai Discovery and what makes their approach distinctive.

**firecrawl-mcp:firecrawl_search**

*Request*

````javascript
{
  "limit": 5,
  "query": "CHai Discovery AI drug discovery how it works technology"
}
````

*Response*

````plaintext
The user has chosen to disallow the tool call.
````

````plaintext
Web Search: CHai Discovery AI drug discovery technology approach
````

> **Chai Discovery** [chaidiscovery.com](https://www.chaidiscovery.com/)
>
> **Chai Discovery Announces $70 million Series A To Transform Molecular Design** [businesswire.com](https://www.businesswire.com/news/home/20250806670137/en/Chai-Discovery-Announces-$70-million-Series-A-To-Transform-Molecular-Design)
>
> **Chai Discovery Unveils Groundbreaking AI Model ...** [icai.org](https://ai.icai.org/articles_details.php?id=99)
>
> **A Complete Overview of Chai-2+** [glbgpt.com](https://www.glbgpt.com/resource/a-complete-overview-of-chai-2)
>
> **Chai Discovery** [linkedin.com](https://www.linkedin.com/company/chaidiscovery)
>
> **Chai Discovery snaps up $70M to slash drug development timelines with AI — TFN** [techfundingnews.com](https://techfundingnews.com/chai-discovery-snaps-70m-to-shrink-drug-discovery-timelines-from-years-to-months-with-ai/)
>
> **Chai-1: revolutionising drug discovery with artificial intelligence — a comprehensive review | by IAforTeachers | STXBP1 Insights | Medium** [medium.com](https://medium.com/stxbp1-insights/chai-1-revolutionising-drug-discovery-with-artificial-intelligence-a-comprehensive-review-f783c77b9400)
>
> **Chai Discovery Raises $70M for AI-Powered Antibody Design** [futureteknow.com](https://futureteknow.com/chai-discovery-ai-antibody-drug-design/)
>
> **Chai Discovery - Products, Competitors, Financials, Employees, Headquarters Locations** [cbinsights.com](https://www.cbinsights.com/company/chai-discovery)
>
> **The Chai Discovery Inflection: How a $70M Series A Signals the Dawn of Engineered Biology** [onhealthcare.tech](https://www.onhealthcare.tech/p/the-chai-discovery-inflection-how)
>
Based on the search results, here's what CHai Discovery does and what makes them different:

## What CHai Discovery Does

CHai Discovery builds AI foundation models that predict and reprogram the interactions between biochemical molecules. Their mission is to transform biology from science into engineering, allowing therapeutics to be designed rather than discovered through trial and error.

They've released two major models:

**Chai-1** (September 2024): An open-source foundation model for molecular structure prediction that can handle proteins, DNA, RNA, and small molecules, outperforming Google DeepMind's AlphaFold on specific tasks.

**Chai-2** (recently launched): A generative AI model for fully de novo antibody design with a hit rate approaching 20%, a dramatic improvement over traditional computational methods which achieved around 0.1%. The system only requires a target antigen and epitope as input to generate entirely new antibodies.

## Key Differentiators

1. **Dramatically better success rates**: Chai-2 achieves a 15-20% hit rate for new antibody designs—a more than 100x improvement over older computational approaches. Traditional lab screening methods require testing millions or billions of antibodies to find viable candidates.

2. **De novo generation capability**: Rather than just optimizing existing molecules, Chai-2 generates entirely new antibody designs from scratch, enabling work on previously "undruggable" targets.

3. **Open-source foundation**: Unlike many competitors, Chai-1 is open-source and available for free for non-commercial use through a web interface, fostering collaborative research and democratizing AI tools.

4. **All-star team**: Founded by Joshua Meier (ex-Absci, Facebook AI, OpenAI), Jack Dent (ex-Stripe), and AI researchers Matthew McPartlon and Jacques Boitreaud, with former Pfizer Chief Scientific Officer Mikael Dolsten on the board.

5. **Speed of execution**: Founded in 2024, they've already raised over $230M total and achieved unicorn status at $1.3B valuation by December 2025—extraordinarily fast progress.

The company essentially aims to turn drug discovery from a lengthy trial-and-error process into a precision engineering discipline, potentially reducing development timelines from years to months.



## Response:
12/15/2025, 9:27:19 AM

You're right - there are indeed a bunch! Let me search for more specific information about how CHai compares to other de novo protein/antibody design companies in this crowded space.

````plaintext
Web Search: CHai Discovery vs competitors Isomorphic Labs Generate Biomedicines Profluent
````

> **La start-up d'IA Chai Discovery lève 70 millions de dollars pour concevoir des médicaments vitaux grâce à des algorithmes - CTOL Digital Solutions FR** [ctol-fr.com](https://www.ctol-fr.com/news/ai-startup-chai-discovery-raises-70-million-design-life-saving-drugs-algorithms/)
>
> **Chai Discovery - Products, Competitors, Financials, Employees, Headquarters Locations** [cbinsights.com](https://www.cbinsights.com/company/chai-discovery)
>
> **Isomorphic Labs - 2025 Company Profile, Team, Funding, Competitors & Financials - Tracxn** [tracxn.com](https://tracxn.com/d/companies/isomorphic-labs/__NeR0B9OwN1j6VmvXJhpEk33vyXBIiwzRwNqeBH3Mp_o)
>
> **The Chai Discovery Inflection: How a $70M Series A Signals the Dawn of Engineered Biology** [onhealthcare.tech](https://www.onhealthcare.tech/p/the-chai-discovery-inflection-how)
>
> **Leading artificial intelligence–driven drug discovery platforms: 2025 landscape and global outlook - ScienceDirect** [sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0031699725075118)
>
> **Exclusive: Biotech startup Profluent says it has found "scaling laws" for AI models for protein design | Fortune** [fortune.com](https://fortune.com/2025/04/16/biotech-profluent-ai-scaling-laws-protein-design-models-opencrispr-openantibodies/)
>
> **Our Tech - Isomorphic Labs** [isomorphiclabs.com](https://www.isomorphiclabs.com/our-tech)
>
> **How AI is changing the way scientists engineer drugs, biosensors, enzymes and more – GeekWire** [geekwire.com](https://www.geekwire.com/2023/how-ai-is-changing-the-way-scientists-make-drugs-biosensors-enzymes-and-more/)
>
> **Isomorphic Labs | Competitive Intelligence Profile** [rivalsense.co](https://rivalsense.co/intel/isomorphic-labs/)
>
> **Unlocking the Future of Biotech: Our Picks for the Top 10 AI Biotech Companies Leading the Charge |** [scispot.com](https://www.scispot.com/blog/unlocking-the-future-of-biotech-top-ai-biotech-companies-leading-the-charge)
>
````plaintext
Web Search: Generate Biomedicines Absci Profluent antibody design comparison
````

> **Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox** [genengnews.com](https://www.genengnews.com/topics/artificial-intelligence/scratch-that-de-novo-antibody-design-enters-the-ai-drug-discovery-toolbox/)
>
> **AI hype vs. reality: Skeptics eye Absci and Generate Biomedicines** [statnews.com](https://www.statnews.com/2025/02/10/ai-drug-development-claims-by-biotech-companies-absci-generate-biomedicines-questioned/)
>
> **Antibody design enters the AI era** [nature.com](https://www.nature.com/articles/d43747-024-00030-w)
>
> **Absci Develops Groundbreaking Machine Learning Models for In-Silico Antibody Design, Powered by NVIDIA | Phoenix** [phoenix-vp.com](https://phoenix-vp.com/absci-develops-groundbreaking-machine-learning-models-for-in-silico-antibody-design-powered-by-nvidia/)
>
> **‘If You Could Hallucinate a Protein’: Profluent Snags $35M for Generative AI Models - Bakar Bio Labs** [bakarlabs.org](https://bio.bakarlabs.org/if-you-could-hallucinate-a-protein-profluent-snags-35m-for-generative-ai-models/)
>
> **7 companies to watch in AI protein design** [statnews.com](https://www.statnews.com/2024/11/05/who-to-know-series-7-biotech-companies-ai-protein-design/)
>
> **Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI | Absci Corp** [absci.com](https://investors.absci.com/news-releases/news-release-details/absci-first-create-and-validate-de-novo-antibodies-zero-shot)
>
> **Designed by AI: the future of antibody drugs - The Pharmaceutical Journal** [pharmaceutical-journal.com](https://pharmaceutical-journal.com/article/feature/designed-by-ai-the-future-of-antibody-drugs)
>
> **AI Promised Faster Drug Discovery. Now It Has to Prove It** [aimmediahouse.com](https://aimmediahouse.com/ai-lifesciences/ai-designed-asthma-drug-phase-3-generate-biomedicines)
>
> **Unlocking de novo antibody design with generative artificial intelligence | bioRxiv** [biorxiv.org](https://www.biorxiv.org/content/10.1101/2023.01.08.523187v1)
>
Great question! The space is indeed crowded. Here's how CHai Discovery differs from other de novo protein design companies:

## Key Differentiators

**1. Dramatically Higher Success Rates**
CHai's biggest claim is their performance metrics. While traditional computational approaches typically achieve around 0.1% success rates, CHai-2 achieves 15-20% hit rates. This is important because even competitors like Absci and Generate:Biomedicines have faced scrutiny over their "de novo" claims.

**2. Controversy in the Field**
The de novo antibody design space has been contentious. Both Absci and Generate:Biomedicines faced criticism in early 2025, with allegations that their de novo pipelines merely produced over-hyped redesigned versions of existing antibodies. For example, Generate's Phase I SARS-CoV-2 antibody candidate GB-0669 was criticized as being only a few mutations away from an existing antibody.

**3. Open Source Strategy**
Unlike most competitors, CHai released Chai-1 as fully open-source. Competitors like:
- **Isomorphic Labs** (Google DeepMind spinout): Has secured partnership deals worth over $3 billion in potential milestones with Eli Lilly and Novartis, but keeps their tech proprietary
- **Generate:Biomedicines**: Has the longest pipeline and is advancing GB-0895, an AI-designed asthma antibody, into two global Phase 3 trials
- **Profluent**: Focuses on gene editing proteins (CRISPR systems) rather than antibodies

**4. Clinical Stage vs. Platform**
The competitive landscape breaks down by maturity:
- **Generate:Biomedicines** ($750M raised): Most clinically advanced with multiple programs in trials
- **Xaira Therapeutics**: Raised $1B+ in Series A (second-largest biotech startup funding ever), co-founded by Nobel laureate David Baker
- **Absci**: Public company with major pharma partnerships (AstraZeneca, Merck deals worth $610M+)
- **CHai Discovery**: Very early stage (founded 2024) but growing extremely fast with strong technical claims

**5. Founder Pedigree**
Interestingly, CHai's CEO Joshua Meier was previously Absci's Lead AI Scientist, where he presented breakthroughs at NVIDIA GTC. So CHai's founder literally came from one of their main competitors and is now building what he presumably believes is a better approach.

**The Bottom Line**
CHai is betting that their superior hit rates (20% vs. 0.1%) and rapid iteration will overcome their late entry. But they're unproven clinically, while Generate already has Phase 3 data coming and Isomorphic has massive pharma partnerships. The real test will be whether CHai's computational advantages translate to actual drugs in patients.



## Response:
12/15/2025, 9:31:30 AM



````plaintext
Web Search: de novo protein design methods diffusion models RFdiffusion ProteinMPNN
````

> **De novo design of protein structure and function with RFdiffusion | Nature** [nature.com](https://www.nature.com/articles/s41586-023-06415-8)
>
> **De novo design of protein structure and function with RFdiffusion - PubMed** [nih.gov](https://pubmed.ncbi.nlm.nih.gov/37433327/)
>
> **Creating Life’s Building Blocks: Models for De Novo Protein Design - Front Line Genomics** [frontlinegenomics.com](https://frontlinegenomics.com/creating-lifes-building-blocks-models-for-de-novo-protein-design/)
>
> **RFdiffusion: A generative model for protein design • Baker Lab** [bakerlab.org](https://www.bakerlab.org/2023/07/11/diffusion-model-for-protein-design/)
>
> **Sparks of function by de novo protein design - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11366440/)
>
> **De novo design of protein structure and function with RFdiffusion - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468394/)
>
> **(PDF) De novo design of protein structure and function with RFdiffusion** [researchgate.net](https://www.researchgate.net/publication/372301153_De_novo_design_of_protein_structure_and_function_with_RFdiffusion)
>
> **Broadly applicable and accurate protein design by integrating structure prediction networks and diffusion generative models | bioRxiv** [biorxiv.org](https://www.biorxiv.org/content/10.1101/2022.12.09.519842v1)
>
> **De novo design of protein structure and function with RFdiffusion (Journal Article) | OSTI.GOV** [osti.gov](https://www.osti.gov/biblio/2420884)
>
> **Software – Institute for Protein Design** [uw.edu](https://www.ipd.uw.edu/software/)
>
````plaintext
Web Search: protein language models ESM Profluent generative antibody design
````

> **Giving Structure to Language: Profluent's AI Models Move toward Precise and Steerable Protein Design** [genengnews.com](https://www.genengnews.com/topics/artificial-intelligence/giving-structure-to-language-profluents-ai-models-move-toward-precise-and-steerable-protein-design/)
>
> **Profluent | Generating Proteins with Atomic-level Control** [profluent.bio](https://www.profluent.bio/media/generating-proteins-with-atomic-level-control)
>
> **Unsupervised evolution of protein and antibody complexes with a structure-informed language model - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11616794/)
>
> **Unsupervised evolution of protein and antibody complexes with a structure-informed language model | Science** [science.org](https://www.science.org/doi/10.1126/science.adk8946)
>
> **Efficient evolution of human antibodies from general protein language models | Nature Biotechnology** [nature.com](https://www.nature.com/articles/s41587-023-01763-2)
>
> **Introducing ProGen3** [profluent.bio](https://www.profluent.bio/showcase/progen3)
>
> **Protein language models: promises, pitfalls and applications** [pipebio.com](https://pipebio.com/blog/protein-language-models)
>
> **A Comprehensive Review of Protein Language Models** [arxiv.org](https://arxiv.org/html/2502.06881v1)
>
> **Profluent | Designing Proteins with Language Models** [profluent.bio](https://www.profluent.bio/media/designing-proteins-with-language-models)
>
> **AI Models for Protein Design are Driving Antibody Engineering - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10361400/)
>
Let me search for more information on investment considerations and business models in this space.

````plaintext
Web Search: AI drug discovery business model platform vs pipeline validation risks
````

> **Progress, Pitfalls, and Impact of AI‐Driven Clinical Trials - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11924158/)
>
> **The Predictive Pipeline: Structuring Drug Development Timelines with AI-Driven Patent Intelligence - DrugPatentWatch – Transform Data into Market Domination** [drugpatentwatch.com](https://www.drugpatentwatch.com/blog/the-predictive-pipeline-structuring-drug-development-timelines-with-ai-driven-patent-intelligence/)
>
> **AI-Driven Drug Discovery: A Comprehensive Review | ACS Omega** [acs.org](https://pubs.acs.org/doi/10.1021/acsomega.5c00549)
>
> **Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11510778/)
>
> **Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond** [biopharmatrend.com](https://www.biopharmatrend.com/business-intelligence/what-is-ai-drug-discovery/)
>
> **Artificial intelligence in drug discovery and development - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7577280/)
>
> **AI In Action: Redefining Drug Discovery and Development - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11800368/)
>
> **Leading artificial intelligence–driven drug discovery platforms: 2025 landscape and global outlook - ScienceDirect** [sciencedirect.com](https://sciencedirect.com/science/article/abs/pii/S0031699725075118)
>
> **AI Applications in the Drug Development Pipeline | IntuitionLabs** [intuitionlabs.ai](https://intuitionlabs.ai/articles/ai-drug-development-pipeline)
>
> **AI in Action: Accelerating the Drug Discovery Pipeline - DrugPatentWatch – Transform Data into Market Domination** [drugpatentwatch.com](https://www.drugpatentwatch.com/blog/ai-in-action-accelerating-the-drug-discovery-pipeline/)
>
Now let me create a comprehensive breakdown for you.

````plaintext
Create File: Creating a comprehensive investment framework document for de novo protein design companies
````

**present_files**

*Request*

````javascript
{
  "filepaths": [
    "/home/claude/protein_design_investment_framework.md"
  ]
}
````

*Response*

````plaintext
Files copied:
Copied /home/claude/protein_design_investment_framework.md to /mnt/user-data/outputs/protein_design_investment_framework.md
````

I've created a comprehensive investment framework for you covering de novo protein design. Here's what's inside:

## Key Sections:

**I. Scientific Methods Breakdown** - Four main approaches with their strengths/weaknesses:
- Diffusion Models (RFdiffusion - structure-first)
- Protein Language Models (ESM, ProGen - sequence-first) 
- Hybrid Approaches (Chai, proseLM - combining both)
- Physics-Based + ML (Schrödinger - traditional + AI)

**II. Technical Validation Metrics** - What to actually ask about when evaluating claims

**III. Investment Framework:**
- Business model assessment (platform vs pipeline vs hybrid)
- Technical moat analysis (what creates real defensibility)
- Stage-based considerations (seed through late-stage)
- Competitive positioning matrix

**IV. Risk Analysis** - Technology risks, market risks, financial risks with mitigation strategies

**V. Due Diligence Questions** - 18 specific questions to ask companies

**VI. Decision Matrix** specifically for Chai Discovery with go/no-go criteria

**VII. Comps & Benchmarks** - How Chai stacks up against Generate, Xaira, Profluent, Absci, etc.

**VIII. Final Recommendations** by investor type

## Bottom Line on Chai:

**The Good:** Elite team (ex-Absci chief AI scientist, OpenAI, Meta), claimed 20% hit rate vs 0.1% baseline is transformational if real, rapid validation from top VCs.

**The Bad:** $1.3B valuation with zero clinical data, no wet-lab, no pharma partnerships announced yet, performance claims need independent validation.

**The Verdict:** High-risk bet on category leadership. Great for early-stage VCs who believe in the team. Too expensive for growth investors without more proof points. Strategic pharma should engage for partnership now.

The framework helps you think through not just Chai but any company in this space systematically.



## Response:
12/15/2025, 10:00:08 AM

No, Claude Code cannot directly access the markdown file I just created. Here's why:

**The Issue:**
- The file I created is in `/mnt/user-data/outputs/` in *this* chat session (Claude web/app)
- Claude Code runs in a separate environment (your terminal/command line)
- These two environments don't share filesystems

**To Get the File to Claude Code:**

1. **Download it first**: Click the download link above for the markdown file
2. **Upload to Claude Code**: In your Claude Code session, you can:
   - Place the file in your working directory
   - Tell Claude Code to reference the file path
   - Or paste relevant sections into your conversation

**Alternative - Use Past Chats Tool:**
If you're in Claude Code and reference "my previous chat about protein design," Claude Code *can* use the `conversation_search` or `recent_chats` tools to find content from this conversation, but it will see the text content, not the file itself as a downloadable artifact.

**Best Practice:**
Tell Claude Code something like: "I have a markdown file about protein design investment framework. Here's the relevant section: [paste section]" or upload the downloaded file to your project directory.

Want me to create a summary version you can easily paste into Claude Code?



## Response:
12/15/2025, 10:02:54 AM

Actually, let me clarify - **Claude Code CAN access the content through conversation_search/recent_chats**, but there's an important nuance:

**What Claude Code CAN see:**
- The full text content of the markdown file (all the analysis, frameworks, recommendations)
- It's in the conversation history, so it's searchable via the past chats tools
- Claude Code could read and reference all that content

**What Claude Code CANNOT do:**
- Download the actual .md file itself as a file
- See it as a separate artifact/attachment
- Access the `/mnt/user-data/outputs/` filesystem from this chat

**Practical Example:**
If you go to Claude Code and say "look at my recent chat about Chai Discovery investment framework," Claude Code would:
✅ Find this conversation
✅ See all the markdown content I created
✅ Be able to discuss it, reference it, build on it

But Claude Code would:
❌ NOT see it as a downloadable file
❌ NOT be able to give you the file directly

**So the answer is:** Claude Code can access the *content* through past chats tools, just not as a file artifact. It would see it as text in our conversation history.

Does that make sense? The content is accessible, just not in file form.



## Response:
12/15/2025, 10:03:25 AM

Perfect! Then you're all set. 

When you're in Claude Code, you can just say something like:

"Look through my recent chats about Chai Discovery and protein design investment framework"

And Claude Code will be able to pull up all the analysis, technical breakdowns, investment frameworks, and recommendations we just created. It'll have access to:

- All the scientific methods (diffusion models, language models, hybrids)
- The investment decision matrix
- Risk analysis
- Due diligence questions
- Competitive comps
- The specific Chai Discovery assessment

So if you want to build on this analysis, create code to track these companies, analyze their patents, or do any other follow-up work, Claude Code will have the full context.



## Response:
12/15/2025, 12:30:32 PM



````plaintext
Web Fetch: Fetched: https://investors.absci.com/static-files/3e874e75-d310-4a7f-8e05-adb3dad22a56
````

This is a goldmine of concrete, quantifiable data. Here are the key takeaways:

## Quantifiable Platform Metrics

**Data Flywheel Scale:**
- **77,000+ sq ft** automated wet lab
- **6-week "lab-in-the-loop" cycles** for continuous model improvement
- Generating **hundreds of millions of sequence-function datapoints** since 2020
- Can test nearly **3 million unique AI-generated designs per week**

**Search Space:**
- Model searches **~10^19 possible antibody sequences** in one step
- This is **1 million times larger** than traditional methods can explore
- For HIV caldera: generated **10,000+ structures**, selected 4 best

**Hit Rates & Performance:**
- pH sensitivity optimization: achieved **10-100x differential** in binding at different pH levels
- HIV caldera: successfully designed binders to an epitope **no natural or synthetic antibody has ever bound**
- HER2 variants: edit distance of up to **12 amino acids in HCDR3** (search space of 20^13)

---

## Pipeline Concrete Data Points

**ABS-201 (Hair Loss / Endometriosis):**
- **>3x extended half-life** vs competitor HMI-115 in NHPs
- **>90% subcutaneous bioavailability** in NHPs
- Predicted **Q8W-Q12W dosing** vs Q2W-Q4W for competitor (2-3 doses over 6 months vs 6-12+ doses)
- Target market: **80 million Americans** with androgenetic alopecia
- Endometriosis peak sales potential: **>$4.5B**
- Formulation: targeting **200mg/mL** concentration vs ~60mg/mL for competitor

**ABS-101 (TL1A for IBD):**
- **2-3x extended half-life** vs first-generation competitors
- **~80% subcutaneous bioavailability** in NHPs
- **200mg/mL** high-concentration formulation achieved
- Market: **$22B+ Global IBD market**, $4.5B for TL1A specifically

---

## Timeline Evidence (AI Speed Claims)

**De Novo Model Evolution:**
- 2022: v1 - First to design/validate zero-shot antibodies
- 2023: v2 - Demonstrated broad applicability (NeurIPS publication)
- 2024: v3 - Designed against epitope with **no known binders** (Large Pharma partnership)
- 2025: v4 - HIV Caldera success (previously "undruggable")

**Development Timelines:**
- ABS-201: Ph1/2a initiation **December 2025**, interim PoC **2H 2026** (~12-18 months to efficacy signal)
- ABS-201 Endo: Ph2 initiation **Q4 2026**, PoC as early as **2H 2027**

---

## Competitive Differentiation Data

**ABS-201 vs HMI-115 (competitor PRLR antibody):**

| Attribute | HMI-115 | ABS-201 |
|-----------|---------|---------|
| Affinity | + | ++ |
| Solubility | - | ++ |
| Stability | - | + |
| Half-life | - | ++ |
| Bioavailability | - | ++ |
| Patent Life | - | ++ |

**ABS-101 (TL1A) - Internalization Data:**
- ABS-101 shows **reduced TL1A complex internalization** vs RVT-3101 (Roche)
- This matters because internalization contributes to ADA (anti-drug antibodies)

---

## Business Model Validation

**Partnerships:**
- **25+ partnered programs** to date
- Partners include: AstraZeneca, Merck, and others
- Anticipate signing **1+ partnerships with Large Pharma in 2025**

**Financial Position:**
- **>$600M capital raised** to date
- **Runway into 1H 2028**
- **~140 employees**
- Locations: Vancouver WA (77K sqft), NYC (AAIR lab), Zug Switzerland

---

## Key Investment Insights from This Deck

**1. Wet Lab is the Moat**
The 77K sqft lab generating millions of datapoints is the real differentiator. This is why Chai (no wet lab) needs to partner or will eventually need to build one.

**2. Half-Life Engineering is Commercially Critical**
Both lead programs (ABS-201, ABS-101) emphasize **2-3x longer half-life** than competitors. This translates to:
- Fewer injections (patient convenience)
- Higher compliance
- Competitive differentiation
- Better commercial positioning

**3. Speed to PoC is Measurable**
They're projecting efficacy readouts in **12-18 months** from trial start. Traditional timelines would be 2-3+ years.

**4. "Undruggable" Targets are the Real Test**
The HIV caldera case study is compelling because:
- No natural antibody exists
- No synthetic antibody has succeeded
- Absci's de novo model found binders
- This validates the "cracking tough epitopes" claim

**5. Platform Generates IP at Scale**
Key quote: "100s to 10,000s of functionally validated sequences" per target. This creates patent thickets and multiple backup candidates.

---

## Red Flags / Watch Items

1. **No approved drugs yet** - still preclinical/Phase 1
2. **ABS-101 being out-licensed** - suggests they're capital-constrained or the asset isn't strategic
3. **Stock is public** - you can see the market's skepticism in the valuation (~$500M market cap for all this)
4. **Competitor HMI-115 validated the mechanism** - Absci is fast-follower, not first-mover on PRLR

---

## Bottom Line

This deck shows what a **mature AI drug discovery platform** looks like with real quantitative evidence. The contrast with Chai is stark:
- Absci: 77K sqft wet lab, millions of datapoints, Phase 1 drugs, 25+ partnerships
- Chai: Open-source model, claimed 20% hit rate, no wet lab, no clinical assets, $1.3B valuation

Absci is trading at ~$500M with all this infrastructure and clinical progress. Chai is at $1.3B with a model and a team. That tells you the market is either undervaluing Absci or overvaluing Chai (or both).





---
Powered by [Claude Exporter](https://www.claudexporter.com)